Menu
← Oncology Approval Tracker
FDA DECISION ·
Apalutamide (Erleada reference)
apalutamide · Zydus Worldwide DMCC
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First generic apalutamide tablets for metastatic castration-sensitive or nonmetastatic castration-resistant prostate cancer.
LAMPGEN ANALYSIS
Why it matters
The first generic creates another sourcing option for androgen receptor blockade in two distinct prostate cancer settings.
What research teams should watch
Continue tracking castration status, oral refill continuity, and drug interactions during any formulary transition.
PRIMARY RECORDS